These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30945328)

  • 1. Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
    Quinquenel A; Godet S; Dartigeas C; Ysebaert L; Dupuis J; Ohanyan H; Collignon A; Gilardin L; Lepretre S; Dilhuydy MS; Vignon M; de Guibert S; Dmytruk N; Durot E; Ghez D; Roos Weil D; Béné MC; Toussaint E; Merabet F; Lévy V; Delmer A; Aurran T
    Am J Hematol; 2019 Jul; 94(7):E183-E185. PubMed ID: 30945328
    [No Abstract]   [Full Text] [Related]  

  • 2. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
    Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
    Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
    Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy A; Claxton DF; Bachow SH; Kaur G; Svoboda J; Nasta SD; Porter D; Landsburg DJ; Schuster SJ; Cheson BD; Kiselev P; Evens AM
    Blood; 2016 Nov; 128(18):2199-2205. PubMed ID: 27601462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
    Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
    Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
    Chung C; Lee R
    Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
    Zinzani PL; Rambaldi A; Gaidano G; Girmenia C; Marchetti M; Pane F; Tura S; Barosi G
    Leuk Res; 2019 Jun; 81():88-94. PubMed ID: 31055248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
    Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
    Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
    Gentile M; Martino EA; Visentin A; Coscia M; Reda G; Sportoletti P; Mauro FR; Laurenti L; Varettoni M; Murru R; Chiarenza A; Vigna E; Mendicino F; Lucia E; Bossio S; Recchia AG; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vitale C; Tripepi G; D'Arrigo G; Angeletti I; Bomben R; Neri A; Cutrona G; Fronza G; Di Raimondo F; Gaidano G; Cuneo A; Foà R; Ferrarini M; Trentin L; Gattei V; Morabito F
    Blood Cancer J; 2020 Sep; 10(9):92. PubMed ID: 32938904
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    Mato AR; Timlin C; Ujjani C; Skarbnik A; Howlett C; Banerjee R; Nabhan C; Schuster SJ
    Br J Haematol; 2018 Apr; 181(2):259-261. PubMed ID: 28220935
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
    Hampel PJ; Larson MC; Kabat B; Call TG; Ding W; Kenderian SS; Bowen D; Boysen J; Schwager SM; Leis JF; Chanan-Khan AA; Muchtar E; Hanson CA; Slager SL; Kay NE; Chaffee KG; Shanafelt TD; Parikh SA
    Br J Haematol; 2018 Nov; 183(3):421-427. PubMed ID: 30117139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Marini BL; Samanas L; Perissinotti AJ
    J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
    de Weerdt I; Koopmans SM; Kater AP; van Gelder M
    Haematologica; 2017 Oct; 102(10):1629-1639. PubMed ID: 28775119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Vitale C; Salvetti C; Griggio V; Porrazzo M; Schiattone L; Zamprogna G; Visentin A; Vassallo F; Cassin R; Rigolin GM; Murru R; Laurenti L; Rivela P; Marchetti M; Pennese E; Gentile M; Boccellato E; Perutelli F; Montalbano MC; De Paoli L; Reda G; Orsucci L; Trentin L; Cuneo A; Tedeschi A; Scarfò L; Gaidano G; Mauro FR; Foà R; Boccadoro M; Coscia M
    Blood; 2021 Jun; 137(25):3507-3517. PubMed ID: 33651883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.
    Ysebaert L; Feugier P; Michallet AS
    Curr Opin Oncol; 2015 Sep; 27(5):365-70. PubMed ID: 26154708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of B-cell receptor signalling in B-cell malignancies.
    Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
    J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.